Is CLDX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.

CLDX (Celldex Therapeutics, Inc) Stock Analysis - Financials

Celldex Therapeutics, Inc (CLDX) is a publicly traded Healthcare sector company. As of September 8, 2026, CLDX trades at $39.13 with a market cap of $3.12B and a P/E ratio of -8.97. CLDX moved -1.46% today. Year to date, CLDX is +44.04%; over the trailing twelve months it is +67.18%. Its 52-week range spans $14.40 to $45.14. Analyst consensus is strong buy with an average price target of $58.79. Rallies surfaces CLDX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are CLDX's key financials?

CLDX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CLDX recently traded at $39.13. Market cap is $3.12B. P/E ratio is -8.97. Revenue is $158.00K.

CLDX Key Metrics

Key financial metrics for CLDX
Metric	Value
Price	$39.13
Market Cap	$3.12B
P/E Ratio	-8.97
EPS	$-4.35
Dividend Yield	0.00%
52-Week High	$45.14
52-Week Low	$14.40
Volume	757.18K
Avg Volume	0
Revenue (TTM)	$158.00K
Net Income	$-300.55M
Gross Margin	0.00%

CLDX Analyst Consensus

14 analysts cover CLDX: 0 strong buy, 13 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $58.79.

Common questions about CLDX

What are CLDX's key financials?: CLDX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. CLDX recently traded at $39.13. Market cap is $3.12B. P/E ratio is -8.97. Revenue is $158.00K.
Is CLDX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLDX. It does not provide personalized investment advice.